StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
9527.SR$74.75+0.33%
Fair $74.75+0.0%

9527.SR

Alf Meem Yaa for Medical Supplies and Equipment Company

Healthcare / Medical DistributionSaudi

$74.75

+0.25 (+0.33%)

Fairly Valued+0.0%Fair Value $74.75Fund rank 31/100 · Data gapFallback financials|
SA 56/C
F-Score: 4/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 32% · confianza 25%

FCF escenarios

weak_data · normalized FCF $7.6M · quality 56.7/100

Data gap 31/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 38/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

56/100

C

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 9527.SRLocal privado en este navegador · Alf Meem Yaa for Medical Supplies and Equipment Company
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$523M

P/E

11.2x

↓

EV/EBITDA

9.6x

↓

ROE

28.6%

↑

Gross Margin

41.1%

↓

Debt/Equity

0.01

↓
52-Week Range$75
$70$140

TradingView lightweight chart

9527.SR price, volumen y niveles de valoración

Último $75.00Periodo +32.0%
Fair value: $74.75

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2021–2024 · 3 años de histórico normalizado

Revenue CAGR

+17.9%

FCF CAGR

—

FCF margin

-1.6%

FCF / Net income

-0.09x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $248.4M · net income $45.4M · FCF $-4.1M

2021-FY → 2024-FY

Gross margin

41.1%-4.8% pts

Operating margin

18.2%+2.0% pts

Net margin

18.3%+4.3% pts

FCF margin

-1.6%-15.0% pts
MetricTTM
2024
2023
2022
2021
Income Statement
Revenue$248.4M$248.4M$220.0M$193.2M$151.4M
Net Income$45.4M$45.4M$33.5M$26.7M$21.2M
EBITDA$52.5M$52.5M$39.8M$31.2M$24.9M
EPS6.496.494.793.813.03
Gross Margin41.1%41.1%43.4%46.7%45.9%
Operating Margin18.2%18.2%15.1%15.5%16.2%
Net Margin18.3%18.3%15.2%13.8%14.0%
Balance Sheet
Debt/Equity0.010.010.020.010.02
Current Ratio3.283.28———
Cash Flow
Free Cash Flow$-4.1M$-4.1M$34.7M$7.6M$20.3M
Returns
ROE28.6%28.6%26.4%24.9%22.7%
Valuation
P/E11.2311.2310.589.48—
EV/EBITDA9.579.577.907.38—
P/B3.313.312.792.35—
Growth & Yield
Revenue Growth12.9%12.9%13.9%27.6%—
EPS Growth35.5%35.5%25.7%25.7%—
Dividend Yield2.6%2.6%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

0.7%

fácil

EPS terminal req.

$6.63

Spread vs growth

34.8%

5Y implied EPS CAGR

4.3%

fácil

EPS terminal req.

$8.03

Spread vs growth

31.2%

10Y implied EPS CAGR

7.1%

razonable

EPS terminal req.

$12.93

Spread vs growth

28.4%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -30.9%

Total return

-30.9%

Start / end P/E

23.5x → 11.6x

EPS bridge

4.79 → 6.49

Residual

-18.1%

EPS growth+35.5%
Multiple rerating-50.9%
Dividend+2.6%
Residual / FX / buybacks / cross-term-18.1%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.